Prognostic Significance of Lewis y Antigen in Resected Stage I and II Non-small Cell Lung Cancer*

    loading  Checking for direct PDF access through Ovid

Abstract

Background

The role of Lewis y (Ley) antigen expression has been studied extensively in predicting the outcome of various malignancies. We evaluated the expression of Ley and its relationship to survival, disease-free survival and other clinicopathologic variables in patients with stage I and II non-small cell lung cancer (NSCLC).

Objective

To investigate the prognostic significance of Ley antigen expression in a large group of well characterized patients with resected stage I and II NSCLC.

Patients

Two hundred and sixty patients with surgically resected stage I (n = 193) and II (n = 67) NSCLC with at least 5-year follow-up were identified.

Results

The median survival for patients with negative expression of Ley (< 50% of cells that were positive) was 46 months, whereas for those with positive expression of Ley (>or=to 50%), the median survival was 54 months (p = 0.99). The disease-free survival for patients with Ley (-) expression was 39 months and 34 months for patients with Ley (+) expression (p = 0.3).

Conclusions

We found no relationship between loss of blood group antigen A and expression of Ley. No statistically significant difference was found in survival between positive and negative expression of Ley antigen in patients with resected stage I and II NSCLC. (CHEST 1998; 114:1309-1315)

Related Topics

    loading  Loading Related Articles